Ara-C increases gastric cancer cell invasion by upregulating CD-147-MMP-2/MMP-9 via the ERK signaling pathway

Oncology Reports

Volumn 33, Issue 4, 2015, Pages 2045-2051

  Yang, Guang Lin ^a   Tao, Hai Rong ^a   Wang, Han Wei ^b   Sun, Yun ^c   Zhang, Li Di ^a   Zhang, Chao ^a   He, Wei ^a   Xu, Mang Hua ^a   Zhao, Jiang Min ^a   Gao, Feng Hou ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b The Third People's Hospital of Bengbu   (China)

^c Dongnan Hospital   (China)

Author keywords

Ara C; CD 147; Gastric cancer cell; Invasion; MMP 2; MMP 9; Proliferation

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CD147 ANTIGEN; CYTARABINE; GELATINASE A; GELATINASE B; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; SMALL INTERFERING RNA; 1,3 BUTADIENE DERIVATIVE; BSG PROTEIN, HUMAN; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; NITRILE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL COUNTING; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR INVASION; UPREGULATION; ZYMOGRAPHY; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; JURKAT CELL LINE; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANTIGENS, CD147; BUTADIENES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYTARABINE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JURKAT CELLS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NITRILES; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; UP-REGULATION;

EID: 84924898328     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3748     Document Type: Article

References (23)

1. Li R, Chen WC, Pang XQ, et al: Combined effect of sCD40L and PI3K siRNA on transplanted tumours growth and microenvironment in nude mice with gastric cancer. Mol Biol Rep 39: 8755-8761, 2012.
2. Pietrantonio F, De Braud F, Da Prat V, et al: A review on biomarkers for prediction of treatment outcome in gastric cancer. Anticancer Res 33: 1257-1266, 2013.
3. Braun S, Kentenich C, Janni W, et al: Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 18: 80-86, 2000.
4. Aogi K, Rai Y, Ito Y, et al: Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan. Cancer Chemother Pharmacol 71: 1427-1433, 2013.
5. Harland S, Staffurth J, Molina A, et al: Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer 49: 3648-3657, 2013.
6. Sawai K, Goi T, Koneri K, et al: Partial response after transcatheter arterial infusion chemotherapy in a patient with systemic chemotherapy-resistant unresectable colon cancer and hepatic metastasis: (case report). World J Surg Oncol 11: 203, 2013.
7. Oyamada Y, Maeshima A, Takeuchi K and Kato R: A case of lung cancer resistant to pemetrexed responding to S-1 monotherapy. Gan To Kagaku Ryoho 40: 781-784, 2013 (In Japanese).
8. Neuzillet C, Hentic O, Rousseau B, et al: FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World J Gastroenterol 18: 4533-4541, 2012.
9. Galmarini CM, Mackey JR and Dumontet C: Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 3: 415-424, 2002.
10. Löwenberg B: Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood 121: 26-28, 2013.
11. Fan X, Wu W, Shi H and Han J: RNA interference targeting CD147 inhibits the invasion of human cervical squamous carcinoma cells by downregulating MMP-9. Cell Biol Int 37: 737-741, 2013.
12. Zhao S, Ma W, Zhang M, et al: High expression of CD147 and MMP-9 is correlated with poor prognosis of triple-negative breast cancer (TNBC) patients. Med Oncol 30: 335, 2013.
13. Piao S, Zhao S, Guo F, et al: Increased expression of CD147 and MMP-9 is correlated with poor prognosis of salivary duct carcinoma. J Cancer Res Clin Oncol 138: 627-635, 2012.
14. Kim JY, Kim WJ, Kim H, et al: The stimulation of CD147 induces MMP-9 expression through ERK and NF-kappaB in macrophages: implication for atherosclerosis. Immune Netw 9: 90-97, 2009.
15. Farabegoli F, Papi A and Orlandi M: (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells. Biosci Rep 31: 99-108, 2011.
16. Chow S, Patel H and Hedley DW: Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors. Cytometry 46: 72-78, 2001.
17. Fukazawa H, Noguchi K, Murakami Y and Uehara Y: Mitogenactivated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway. Mol Cancer Ther 1: 303-309, 2002.
18. Sunayama J, Matsuda K, Sato A, et al: Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 28: 1930-1939, 2010.
19. Hao JL, Cozzi PJ, Khatri A, et al: CD147/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer. Curr Cancer Drug Targets 10: 287-306, 2010.
20. Kanekura T and Chen X: CD147/basigin promotes progression of malignant melanoma and other cancers. J Dermatol Sci 57: 149-154, 2010.
21. Nabeshima K, Iwasaki H, Koga K, et al: Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int 56: 359-367, 2006.
22. Boulos S, Meloni BP, Arthur PG, et al: Evidence that intracellular cyclophilin A and cyclophilin A/CD147 receptor-mediated ERK1/2 signalling can protect neurons against in vitro oxidative and ischemic injury. Neurobiol Dis 25: 54-64, 2007.
23. Kim K, Kim H, Jeong K, et al: Release of overexpressed CypB activates ERK signaling through CD147 binding for hepatoma cell resistance to oxidative stress. Apoptosis 17: 784-796, 2012.